ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ORMP vs ALXO // RSI-14 & 200D SMA MOMENTUM

Oramed Pharmaceuticals Inc. (NASDAQ) VS. ALX Oncology Holdings Inc. (NASDAQ) • 15-METRIC TALLY: ORMP 1 — ALXO 3
▲ RSI-14 & 200D SMA MOMENTUM LEADER: ALXO
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORMP VS. ALXO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ORMP ALXO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 0.70% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -7.80% -35.00% +27.20 ORMP /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -5.20% — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin 3.80% — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 ALXO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum ACTIVE 35.7 56.4 -20.70 ALXO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $166.4M $171.1M -$4.8M ALXO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ORMP REV ALXO REV ORMP GROSS % ALXO GROSS % ORMP FCF ALXO FCF
FY 2025 $2.0M $291.3M 0.7% — -$9.2M -$84.4M
FY 2024 $35.8M $398.9M — — -$8.4M -$122.4M
FY 2023 $1.3M $476.8M — — -$10.3M -$130.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORMP // BETA —
ALXO // BETA —